{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:53:12Z","timestamp":1789609992142,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40265-022-01700-8","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:31:38Z","timestamp":1648513898000},"page":"691-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Gefapixant: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"1700_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pupt.2019.03.006","volume":"56","author":"D Muccino","year":"2019","unstructured":"Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulm Pharmacol Ther. 2019;56:75\u20138.","journal-title":"Pulm Pharmacol Ther"},{"key":"1700_CR2","unstructured":"Kyorin. MSD K.K. receives manufacturing and marketing approval of LYFNUA\u00ae tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough [media release]. 20 Jan 2022. http:\/\/www.kyorin-pharm.com."},{"key":"1700_CR3","unstructured":"Merck AG. Merck Provides U.S. and Japan regulatory update for gefapixant [media release]. 24 Jan 2022. http:\/\/www.merck.com."},{"key":"1700_CR4","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.autneu.2021.102859","volume":"235","author":"AP Ford","year":"2021","unstructured":"Ford AP, Dillon MP, Kitt MM, et al. The discovery and development of gefapixant. Auton Neurosci. 2021;235:102859.","journal-title":"Auton Neurosci."},{"issue":"2","key":"1700_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","volume":"7","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Afzal AS, Smith JA, et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther. 2021;7(2):471\u201386.","journal-title":"Pulm Ther."},{"key":"1700_CR6","unstructured":"Roche. Roche licenses first-in-class treatments for chronic pain to afferent pharmaceuticals; afferent secures $23 million in series A financing [media release]. 17 Dec 2009. http:\/\/www.roche.com."},{"key":"1700_CR7","unstructured":"Merck Co. Merck announces second-quarter 2016 financial results [media release]. 29 Jul 2016. http:\/\/www.merck.com."},{"key":"1700_CR8","unstructured":"Kyorin. MSD and KYORIN conclude distribution agreement of gefapixant citrate, a treatment for chronic cough, in Japan [media release]. 26 Apr 2021. http:\/\/www.kyorin-pharm.com."},{"issue":"13","key":"1700_CR9","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/bph.14677","volume":"176","author":"D Richards","year":"2019","unstructured":"Richards D, Gever JR, Ford AP, et al. Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol. 2019;176(13):2279\u201391.","journal-title":"Br J Pharmacol"},{"key":"1700_CR10","unstructured":"MSD. Lyfnua\u00ae tablets 45 mg [Japanese prescribing information]. 2022. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170050_22900A0F1027_1_02. Accessed 7 Mar 2022."},{"issue":"1","key":"1700_CR11","doi-asserted-by":"publisher","first-page":"e00924","DOI":"10.1002\/prp2.924","volume":"10","author":"JC Nussbaum","year":"2022","unstructured":"Nussbaum JC, Hussain A, Ma B, et al. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Pharmacol Res Perspect. 2022;10(1):e00924.","journal-title":"Pharmacol Res Perspect."},{"key":"1700_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpdd.1047","volume":"11","author":"JB McCrea","year":"2021","unstructured":"McCrea JB, Hussain A, Ma B, et al. Assessment of pharmacokinetic interaction between gefapixant (MK-7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin. Clin Pharmacol Drug Dev. 2021;11:406\u201312. https:\/\/doi.org\/10.1002\/cpdd.1047.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1700_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cpdd.988","volume":"11","author":"JC Nussbaum","year":"2022","unstructured":"Nussbaum JC, Hussain A, Ma B, et al. Assessment of the effect of pyrimethamine, a potent inhibitor of multidrug and toxin extrusion protein 1\/2K, on the pharmacokinetics of gefapixant (MK-7264), a P2X3 receptor antagonist. Clin Pharmacol Drug Deliv. 2022;11(1):123\u20138.","journal-title":"Clin Pharmacol Drug Deliv."},{"key":"1700_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02348-5","author":"L McGarvey","year":"2022","unstructured":"McGarvey L, Birring S, Morice A, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022. https:\/\/doi.org\/10.1016\/S0140-6736(21)02348-5.","journal-title":"Lancet"},{"issue":"suppl 65","key":"1700_CR15","first-page":"OA1588","volume":"58","author":"P Dicpinigaitis","year":"2021","unstructured":"Dicpinigaitis P, Birring SS, Morice A, et al. Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant. Eur Respir J. 2021;58(suppl 65):OA1588.","journal-title":"Eur Respir J"},{"issue":"8","key":"1700_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775\u201385.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1700_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01615-2019","volume":"55","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Butera P, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55(3):1901615. https:\/\/doi.org\/10.1183\/13993003.01615-2019.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1700_CR18","first-page":"A7776","volume":"201","author":"S Birring","year":"2020","unstructured":"Birring S, Cardozo L, Dmochowski R, et al. A phase 3b trial evaluating the efficacy of gefapixant in reducing stress urinary incontinence in women with chronic cough. Am J Respir Crit Care Med Conf Am Thorac Soc Int Conf ATS. 2020;201(1):A7776.","journal-title":"Am J Respir Crit Care Med Conf Am Thorac Soc Int Conf ATS"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01700-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:21:15Z","timestamp":1700371275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01700-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01700-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"28 March 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}